Navigation Links
David M. Kendall, M.D., Named Distinguished Medical Fellow at Lilly
Date:5/18/2011

INDIANAPOLIS, May 18, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that David M. Kendall, M.D., currently chief scientific and medical officer of the American Diabetes Association, has been named distinguished medical fellow for Lilly. He will transition from his current role in late-July.

In his new role, Kendall will serve as a senior medical advisor for Lilly Diabetes in advocacy and clinical science communities and as a representative to the professional medical community. In addition, he will help provide scientific direction for Lilly in diabetes discovery and clinical development. Other key responsibilities will include the support of Lilly's medical education efforts and diabetes healthcare evaluation programs.

"David brings a critical external view, including the insights he gained while at the American Diabetes Association," said Enrique Conterno, president of Lilly Diabetes. "We are working hard to gain leadership in diabetes care, and that leadership must start with an understanding of the needs of patients and health care providers."

Kendall will report to Robert Heine, M.D., vice president medical affairs, Lilly Diabetes.

"With his background as a clinician, researcher and diabetes advocate, David is the ideal candidate for this position," said Heine. "His focus, passion and understanding of diabetes care will enable us to create ever better solutions for people living with diabetes."

About David Kendall

Kendall joins Lilly Diabetes from the American Diabetes Association, where he serves as scientific and medical officer and has been responsible for the oversight of the Association's research programs, medical affairs, medical education, international affairs, medical information and community programs since 2009.

Kendall also is an associate professor of medicine at the University of Minnesota and an adjunct medical director at the International Diabetes Center, both located in Minneapolis, Minnesota.

Prior to these appointments, Kendall held a number of leadership positions at the International Diabetes Center, and served as faculty at the University of Minnesota Medical School.

Kendall's experience in diabetes spans nearly 25 years, with a research focus on the clinical management of type 1 and type 2 diabetes, emerging novel therapies as well as the treatment and prevention of diabetes complications. He is the author of more than 150 original manuscripts, chapters and professional reviews and a former NIH clinical investigator for both the National Institutes of Diabetes, Digestive and Kidney Diseases and the National Heart, Lung and Blood Institute.

Kendall received his bachelor's degree from St. Olaf College in Northfield, Minnesota, and earned his M.D. and completed his post doctoral training in Diabetes, Endocrinology and Metabolism at the University of Minnesota Medical School in Minneapolis.

About Lilly Diabetes

For more than 85 years, Lilly has been a worldwide leader in pioneering industry-leading solutions to support people living with and treating diabetes. Lilly introduced the world's first commercial insulin in 1923, and remains at the forefront of medical and delivery device innovation to manage diabetes. Lilly is also committed to providing solutions beyond therapy - practical tools, education, and support programs to help overcome barriers to success along the diabetes journey. At Lilly, the journeys of each person living with or treating diabetes inspire ours. For more information, visit www.lillydiabetes.com.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

P-LLY

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Board of Directors of Kinex Pharmaceuticals Appoints Dr. David Hangauer as Chief Scientific Officer
2. Dr. David B. Samadi Discusses Why Robotic Surgery is Quickly Becoming the Go-To Standard for Prostate Cancer Treatment
3. Law Offices of John David Hart: DePuy Recalled Hip Device Lawsuit Filed by Houston Woman
4. St. Davids HealthCare Takes Robotic-Assisted Surgery to the Next Level With the Texas Institute for Robotic Surgery at St. Davids North Austin Medical Center
5. International Prostate Cancer Treatment Expert Dr. David B. Samadi Supports Kenyan Minister of Medical Services, Peter Anyang Nyongos Decision to Travel to the U.S. for Prostate Cancer Treatment
6. Watson Promotes David Buchen, R. Todd Joyce to Executive Vice President
7. Adeona Mourns the Passing of David A. Newsome, M.D., Senior Vice President of Research & Development
8. Codexis Names David Anton CTO & SVP, Process Development & Manufacturing
9. Cayenne Medical, Inc. Appoints David B. Springer President & CEO
10. Corium International Adds Dr. Bhaskar Chaudhuri and David Greenwood to Board of Directors
11. Robotic Surgery Expert Dr. David Samadi, MD Determines Live Robotic Prostate Cancer Surgeries During Israel Trip A Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... -- According to a new market research ... by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application (Drug ... Hospitals/ Clinics) - Forecast to 2021", published by MarketsandMarkets, ... the forecast period of 2016 to 2021. This market ... from USD 117.3 Million in 2016, at a CAGR ...
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... and co-development agreement with Therawis Diagnostics GmbH to develop and ... to develop and market PITX2 as a marker to predict ... breast cancer patients. "We are pleased to partner ...
(Date:5/25/2016)... , May 25, 2016  According to Kalorama ... $381 billion in 2015.  Though these are challenging ... of opportunity for success for companies that remain ... search of new growth prospects medical device companies ... research and development (R&D) than do companies in ...
Breaking Medicine Technology:
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, ... ... has partnered with Mediaplanet to help educate the many who are unaware of ... section dedicated to aphasia will run within the “Stroke Awareness” campaign. , The ...
(Date:5/27/2016)... ... May 27, 2016 , ... Each year ... medicine. Allison Outerbridge is this year’s Life University winner of a ... the university’s Student Leadership Awards ceremony. , Outerbridge is approaching her last quarter ...
(Date:5/26/2016)... , ... May 26, 2016 , ... W.S. Badger ... has been honored with a 2016 When Work Works Award for its use of ... of the national When Work Works project administered by the Families and Work Institute ...
(Date:5/26/2016)... ... ... Connor Sports, through its Connor Cares initiative, will continue to expand ... Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and final WNBA ... levels of the game, Connor Sports has committed to a significantly increased focus on ...
(Date:5/26/2016)... , ... May 26, 2016 , ... There are nearly ... than 32 million cancer survivors worldwide. On Sunday, June 5, 2016, communities around the ... National Cancer Survivors Day®. , National Cancer Survivors Day® is an annual worldwide ...
Breaking Medicine News(10 mins):